Company/Division name | CoImmune1 |
Parent company | Genexine |
Type of work | Manufacturing |
Reshoring category: | Foreign Direct Investment |
Year reshoring announced: | 2019 |
Capital investment ($): | 11.1 |
Country(ies) from which reshored: | Korea, Republic of |
City reshored to: | Durham |
State(s) reshored to: | NC |
If relevant, work nearshored to: | - |
Industry(ies): | Chemicals |
Product(s) reshored | immunotherapies |
What domestic positive factors made reshoring more attractive? | Automation/technology, Proximity to customers/market, Under-utilized capacity |